Clinical Trials Logo

Clinical Trial Summary

Tenofovir alafenamide (TAF), active against both HIV and HBV, demonstrates similar antiviral efficacy but improved renal and bone safety compared to tenofovir disoproxil fumarate (TDF) in HIV-1-infected patients. HIV-1-infected patients whose estimated glomerular filtration rate (eGFR) between 30-69 mL/min were shown to have minimal change in eGFR and improved proteinuria, albuminuria, and bone mineral density after switching to a single-tablet regimen containing Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (EVG/cob/FTC/TAF). For treatment of chronic HBV infection, a similar proportion of HBV-monoinfected patients who received TAF and those who received TDF achieved undetectable HBV DNA at 48 weeks of therapy. Although TAF is effective for HIV and HBV suppression, data on efficacy of TAF are limited among patients co-infected with both viruses. Currently, only one open-label, single-arm study had investigated the efficacy and safety of TAF in HIV/HBV-coinfected patients. In this study, 72 HIV/HBV-coinfected patients switching to EVG/cob/FTC/TAF were enrolled, and 91.7% of them maintained or achieved virologic suppression for both HIV and HBV at 48 weeks of therapy. Seroconversion occurred in 2.9% of HBsAg-positive participants and in 3.3% of HBeAg-positive participants. Improvements in eGFR and declines in markers of bone turnover of the participants were observed. The limitations of the above study are the small sample size. Taiwan is a country hyperendemic for HBV infection, with 19.8% of HIV-positive patients who were born before the implementation of nationwide neonatal vaccination in 1986 had concurrent chronic HBV infection. To further the understanding of the difference between TAF- and TDF-containing combination antiretroviral therapy among HIV/HBV-coinfected patients, the investigators plan to conduct an observational study to evaluate the efficacy and safety of EVG/cob/FTC/TAF as maintenance treatment of HIV/HBV-coinfected patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03425994
Study type Observational [Patient Registry]
Source National Taiwan University Hospital
Contact
Status Active, not recruiting
Phase
Start date February 6, 2018
Completion date October 11, 2019

See also
  Status Clinical Trial Phase
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Terminated NCT04051957 - Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury Phase 2
Completed NCT04985292 - Does Probiotic Supplementation Prevent Kidney Injury During Strenuous Physical Exercise? N/A
Completed NCT04933604 - LPN in Patients With High-complex Renal Tumors
Recruiting NCT05229328 - Study on the Establishment of a System for Early Warning and Prognostic Evaluation of Patients With Sepsis
Completed NCT02242006 - Antimicrobial Pharmacokinetics in Critically Ill Adults During Sustained Low Efficiency Dialysis (SLED)
Terminated NCT05747053 - Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
Completed NCT03407573 - Restrictive vs Liberal Transfusion Strategy on Cardiac Injury in Patients Undergoing Surgery for Fractured Neck Of Femur N/A
Withdrawn NCT00793013 - Airway Pressure Release Ventilation (APRV) Compared to ARDSnet Ventilation Phase 2
Not yet recruiting NCT06108765 - Acute Kidney Injury in Poly Trauma Patients
Recruiting NCT05155358 - Study on the Establishment of a System for Early Warning and Prognostic Evaluation of Patients With Heat Stroke
Completed NCT06008223 - Clinical Analysis of Vitamin B6 in Sepsis N/A
Completed NCT04869462 - DS Titanium Ligation Clip in Urology (Prostatectomy and Nephrectomy)
Recruiting NCT04626323 - Randomized Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease Phase 2
Active, not recruiting NCT02037321 - Meta-Analyses of the Effect of Vegetable Protein for Animal Protein on Cardiometabolic Risk N/A
Completed NCT00819871 - Nuclear Factor Kappa-B (NFKB1) Polymorphism and Organ Injury After Cardiac Surgery N/A
Recruiting NCT05812755 - SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery Phase 4
Recruiting NCT04902846 - Immune Checkpoint Inhibitors Nephrotoxicity
Recruiting NCT04752293 - Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
Completed NCT03139123 - Prevalence of Hypotension Associated With Preload Dependence During Continuous Renal Replacement Therapy